Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$2.31 - $4.99 $273,273 - $590,317
118,300 New
118,300 $402,000
Q2 2023

Aug 14, 2023

BUY
$6.69 - $12.25 $102,357 - $187,425
15,300 New
15,300 $159,000

Others Institutions Holding CVAC

About CureVac N.V.


  • Ticker CVAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,467,008
  • Market Cap $538M
  • Description
  • CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...
More about CVAC
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.